Apeiron's Christian Angermayer on using psychedelic drugs for mental health treatment - CNBC

Psychedelic drug therapy for serious mental illness gets political and investor attention in Christian Angermayer's CNBC discussion. Angermayer, founder of Apeiron Investment Group, joins CNBC's Squawk Box to talk about President Trump's executive order directing government agencies to accelerate psychedelic treatments, and how that move affects momentum in the psychedelics market. The conversation also covers investor appetite for psychedelic companies and broader expectations for how psychedelics are moving toward mainstream mental health treatment pathways.